Background: Peripheral arterial disease (PAD) has a significant negative impact on the quality of life of individuals. Understanding the experiences of people living with PAD will be useful in developing comprehensive patient-centred secondary prevention therapies for this population.
Aim: The aim of this study is to identify first-hand accounts of patients' experiences of living with PAD.
Methods: Six databases (CINALH, PsyclNFO, MEDLINE, AMED, EMBASE, Social citation index/Science citation index via Web of Science (WOS)) and reference lists of identified studies were searched until September 2017 (updated February 2018). Qualitative studies reporting patients' account of living with PAD were eligible for inclusion. A framework thematic synthesis was implemented.
Results: Fourteen studies with 360 participants were included. Pain and walking limitation were recurrent among the varied symptom descriptions. Patients' ignorance and trivialisation of symptoms contributed to delays in diagnosis. Inadequate engagement in disease understanding and treatment decisions meant patients had poor attitudes towards walking treatments and unrealistic expectations about surgery. Depending on symptom progression, patients battle with walking impairment, powerlessness, and loss of independence which were a source of burden to them. Lack of disease understanding is central through patients' journey with PAD and, although they subsequently began adaptation to long term living with PAD, many worried about their future.
Conclusions: Disease understanding is vital across the illness trajectory in patients with PAD. Although certain experiences are common throughout patient journey, some might be unique to a particular stage (e.g. unrealistic expectation about surgery, or rationale of walking in spite of pain in a supervised exercise program). Given that PAD is an overarching construct ranging from the mildest form of intermittent claudication to severe critical limb ischemia with ulceration and gangrene, consideration of important patient constructs specific to each stage of the disease may enhance treatment success. Systematic review registration CRD42017070417.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237376 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0207456 | PLOS |
Curr Med Res Opin
January 2025
Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Objective: To identify factors that may influence health-seeking behaviors and health system interactions from the perspective of Black patients with lung cancer (LC) or peripheral artery disease (PAD).
Methods: Semi-structured interviews were conducted virtually with Black patients in the United States. Thematic analysis of interview transcripts was performed.
Biomedicines
December 2024
Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
: The aim of the study was to assess the effect of high-intensity focused electromagnetic (HIFEM) technology in the treatment of female stress urinary incontinence (SUI). : 20 women with SUI were delivered a treatment course with HIFEM technology. Patients attended 6 therapies scheduled twice a week.
View Article and Find Full Text PDFBiosensors (Basel)
December 2024
Biomedical Science and Engineering Department, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea.
Detecting and tracking the preclinical stages of Alzheimer's disease (AD) is now of particular interest due to the aging of the world's population. AD is the most common cause of dementia, affecting the daily lives of those afflicted. Approaches in development can accelerate the evaluation of the preclinical stages of AD and facilitate early treatment and the prevention of symptom progression.
View Article and Find Full Text PDFImmunotherapy
January 2025
Division of Basic and Clinical Immunology, University of California, Irvine, CA, USA.
This report delves into the challenges and potential solutions associated with flexible, customized subcutaneous immunoglobulin (SCIG) infusion regimens for patients with primary antibody deficiency disease (PAD). Advances in the treatment of inborn errors of immunity, particularly PAD, have converted fatal diseases into chronic, complex, long-term conditions that make adherence to treatment a critical issue. Conventional SCIG infusion regimens, while clinically effective, may not always align with the varied lifestyles, changing lifestyles and commitments of patients which can lead to missed doses, diminishing adherence thus posing potential health risks and compromising the overall effectiveness of treatment.
View Article and Find Full Text PDFBMJ Open
December 2024
School of Health, University of the Sunshine Coast, Sippy Downs, Queensland, Australia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!